-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Deferiprone-[d3]
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1346601-82-8.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1346601-82-8 |
| Description | Deferiprone-[d3] is a labelled product of Deferiprone, which is an iron chelator. |
Product Information
| Synonyms | Deferiprone D3; 1,2-Dimethyl-3-hydroxypyrid-4-one-d3; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridinone-d3 |
| IUPAC Name | 3-hydroxy-2-methyl-1-(trideuteriomethyl)pyridin-4-one |
| Molecular Weight | 142.17 |
| Molecular Formula | C7H6D3NO2 |
| Canonical SMILES | CC1=C(C(=O)C=CN1C)O |
| InChI | InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3/i2D3 |
| InChIKey | TZXKOCQBRNJULO-BMSJAHLVSA-N |
| Boiling Point | 232.7±40.0 °C at 760 mmHg |
| Melting Point | >244°C |
| Flash Point | 94.5±27.3 °C |
| Purity | 95% by HPLC; 95% atom D |
| Density | 1.2±0.1 g/cm3 |
| Solubility | Soluble in Methanol, Water |
| Appearance | Off-White Solid |
| Storage | Store at -20°C |
| Complexity | 228 |
| Exact Mass | 142.082158768 |
| Index Of Refraction | 1.565 |
| In Vitro | Deferiprone (100 μM) protects muscle cells with doxorubicin-induced release of Lactate dehydrogenase. Deferiprone (300 μM) quickly and efficiently removes ferric ions (III) from doxorubicin complexes. Deferiprone (300 μM) rapidly enters myocytes and displaces iron ions from the intracellular iron-calcein complex captured by fluorescence quenching, indicating that in myocytes, deferiprone should also be able to replace iron ions in its doxorubicin complex. In the xanthine oxidase/xanthine superoxide generation system, Deferiprone (3 mM) is also able to greatly reduce the hydroxyl radical production of the iron ion(III)-doxorubicin complex. Deferiprone (0.5 mM) increases the clearance of free iron from RBC membranes in a time-dose-dependent manner.Deferiprone (0.3 mM) effectively inhibits the transfer of radioactive iron from iron-loaded heart cells and protects or restores mitochondrial respiratory enzyme activity. In iron-loaded heart cells, Deferiprone (1 mM) leads to a sharp decrease in complex I-III activity. Deferiprone exhibited cytotoxic effects on human tumor cell lines HSC-2, HSC-3 and HL-60 with IC50s of 13.5 μg/ml, 9.9 μg/ml and 10.6 μg/ml, and HK1 cytotoxicity to HL-60 and HSC-2 cells was reduced inthe presence of FeCl3. Deferiprone (100 μg/ml) induces internucleosome DNA disruption in HL-60 cells, but adds FeCl3 to inhibit DNA disruption. Deferiprone (100 μg/ml) activates Caspase 3, 8, and 9 in HSC-2 cells. |
| In Vivo | In rabbits, Deferiprone (100 mg/kg) reduced mean basilar artery cross-sectional area by 24%. In rabbits, Deferiprone (100 mg/kg) combined with subarachnoid hemorrhage (SAH) exhibits a variable number of endoelastic membrane folds. |
| Target | HCV; Ferroptosis |
| Vapor Pressure | 0.0±1.0 mmHg at 25°C |
| XLogP3-AA | 0.5 |